|Mr. Robert F. Apple||Chief Exec. Officer, Pres and Director||813.98k||67.2k||1966|
|Mr. Fred M. Powell CPA||Exec. VP & CFO||58.95k||N/A||1961|
|Mr. Keith Muckenhirn||Principal Accounting Officer, VP of Fin. and Corp. Controller||339.34k||19.82k||1963|
|Mr. Peter J. Graham Esq.||Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec.||509.17k||N/A||1967|
|Edward Kessig||VP of Sales||N/A||N/A||N/A|
Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector II needle-free auto injectors to administer human growth hormone for patients with growth retardation; and VIBEX disposable pressure-assisted auto injectors. In addition, the company develops XYOSTED for the treatment of testosterone deficiency in adult males; VIBEX auto injectors for treating anaphylaxis; and disposable pen injectors for diabetes and osteoporosis. It has strategic alliances with Teva Pharmaceutical Industries, Ltd. and AMAG Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.
Antares Pharma, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 5. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 7; Compensation: 6.